Page 21 - 2019_05-HaematologicaMondo-web

Editorials
patients, and it defines an important, if still inadequate, benchmark for mogamulizumab in this patient population. The study also exemplifies the futility of standard salvage chemotherapy in R/R ATL, highlighting the importance of ATL patients having access to investigational therapies. Finally, clinically meaningful improvements were evident even after patients had progressed per protocol, underlining shortcomings in the standardized ATL response criteria.
In conclusion, although responses rates were lower than those observed in Japanese studies, performed in a lower risk population with less stringent efficacy end points, the data reported by Phillips et al. support the con- clusion that mogamulizumab is a better treatment option in the second line for R/R western ATL compared to stan- dard chemotherapy, and it should be considered when clinical trials are not available.
References
1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77(12):7415-7419.
2. Bangham CR. HTLV-1 infections. J Clin Pathol. 2000;53(8):581-586.
3. Phillips AA, Harewood JCK. Adult T Cell Leukemia-Lymphoma (ATL): State of the Art. Curr Hematol Malig Rep. 2018;13(4):300-307.
4. Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a
multicenter phase II study. J Clin Oncol. 2012;10;30(8):837-842.
5. Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II
study. Br J Haematol. 2015;169(5):672-682.
6. MalpicaL,PimentelA,ReisIM,etal.Epidemiology,clinicalfeatures,
and outcome of HTLV-1-related ATLL in an area of prevalence in the
United States. Blood Adv. 2018; 2(6):607-620.
7. Phillips AA, Shapira I, Willim RD, et al. A critical analysis of prog-
nostic factors in North American patients with human T-cell lym- photropic virus type-1-associated adult T-cell leukemia/lymphoma:
a multicenter clinicopathologic experience and new prognostic
score. Cancer. 2010;116(14):3438-3446.
8. Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus
investigator choice of chemotherapy regimen in relapsed/refractory
adult T-cell leukemia/lymphoma. Haematologica. xxx
9. Gessain A, Cassar O. Epidemiological Aspects and World
Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.
10. Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci U S A.
1983;80(12):3618-3622.
11. BanghamCRM,MatsuokaM.HumanT-cellleukaemiavirustype1:
parasitism and pathogenesis. Philos Trans R Soc Lond B Biol Sci.
2017;372(1732).
12. FujikawaD,NakagawaS,HoriM,etal.Polycomb-dependentepige-
netic landscape in adult T-cell leukemia. Blood. 2016;127(14):1790-
1802.
13. Baratella M, Forlani G, Accolla RS. HTLV-1 HBZ Viral Protein: A Key
Player in HTLV-1 Mediated Diseases. Front Microbiol. 2017;8:2615. 14. Kataoka K, Iwanaga M, Yasunaga JI, et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
Blood. 2018;131(2):215-225.
15. Mehta-Shah N, Ratner L, Horwitz SM. Adult T-Cell
Leukemia/Lymphoma. J Oncol Pract. 2017;13(8):487-492.
16. Cook LB, Fuji S, Hermine O, et al. Revised Adult T-Cell Leukemia- Lymphoma International Consensus Meeting Report. J Clin Oncol.
2019;37(8):677-687.
17. ShahUA,ChungEY,GiriczO,etal.NorthAmericanATLLhasadis-
tinct mutational and transcriptional profile and responds to epigenet-
ic therapies. Blood. 2018;132(14):1507-1518.
18. KatsuyaH,IshitsukaK,UtsunomiyaA,etal.Treatmentandsurvival
among 1594 patients with ATL. Blood. 2015;126(24):2570-2577.
19. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lym- phoma: Japan Clinical Oncology Group Study JCOG9801. J Clin
Oncol. 2007;25(34):5458-5464.
20. IshidaT,HishizawaM,KatoK,etal.Allogeneichematopoieticstem
cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120(8):1734-1741.
21. Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022-2029.
22. Sakamoto Y, Ishida T, Masaki A, et al. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment. Blood. 2018;132(7):758-761.
haematologica | 2019; 104(5)
867